BUSINESS

Hokuriku Downpours Cripple Some Drug Deliveries; Wholesalers Report No Damage

By Tatsuya Otsuka August 28, 2026

Record-breaking rainfall hit Ishikawa and Toyama prefectures on August 27, prompting the highest-level emergency alert, with some drug deliveries suspended due to poor road conditions even as wholesalers reported no injuries or damage to their facilities.

Jiho contacted five wholesalers operating in the Hokuriku central Japan region, where the prefectures are located, on the same day. Medipal Holdings, Suzuken, Toho Holdings, Alfresa Holdings, which operates in Hokuriku through its Kanazawa-based subsidiary Meisho, and local wholesaler Fines all confirmed no injuries to employees or damage to their business sites.

While most reported no major impact on drug deliveries, Fines had to cancel some of its twice-daily deliveries in the Himi area of Toyama, one of the hardest-hit locations. Some deliveries also could not be made in parts of the Hakui area in Ishikawa.

Partial expressway closures also resulted in some deliveries taking longer than usual.

Heavy rain is forecast to continue in the Hokuriku region through August 28, with wholesalers remaining on alert for further disruption while prioritizing employee safety.

BUSINESS

Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…

By Shinya Sato

More than a year after Dupixent (dupilumab) became the first antibody therapy approved for COPD in Japan, drug makers are…

By Philip Carrigan

A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…

Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…

By Ken Yoshino

The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…

The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…

Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…

Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…